Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F13%3A10209785" target="_blank" >RIV/00216208:11130/13:10209785 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/13:10209785

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00467-012-2332-4" target="_blank" >http://dx.doi.org/10.1007/s00467-012-2332-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00467-012-2332-4" target="_blank" >10.1007/s00467-012-2332-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis

Popis výsledku v původním jazyce

Rituximab has proven effective in the treatment of complicated granulomatosis with polyangiitis (Wegener's, GPA). Two controlled trials in adults demonstrated beneficial effects of rituximab compared to cyclophosphamide in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis to induce remission and to treat relapses. Pediatric experience with rituximab in GPA is limited; the impact on renal function is unknown. We report a female adolescent with GPA and necrotizing glomerulonephritis that lead to end-stage renal disease (ESRD). After 22 months of peritoneal dialysis, she still experienced relapses and major treatment-associated adverse effects. After a single dose of rituximab, she rapidly achieved clinical remission and, unexpectedly, steadily recovered glomerular filtration rate, plateauing at 25 ml/min/1.73 m(2). Peritoneal dialysis could be discontinued for 16 months. This case documents a potent beneficial effect of rituximab on renal manifestation of GPA even in long-

Název v anglickém jazyce

Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis

Popis výsledku anglicky

Rituximab has proven effective in the treatment of complicated granulomatosis with polyangiitis (Wegener's, GPA). Two controlled trials in adults demonstrated beneficial effects of rituximab compared to cyclophosphamide in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis to induce remission and to treat relapses. Pediatric experience with rituximab in GPA is limited; the impact on renal function is unknown. We report a female adolescent with GPA and necrotizing glomerulonephritis that lead to end-stage renal disease (ESRD). After 22 months of peritoneal dialysis, she still experienced relapses and major treatment-associated adverse effects. After a single dose of rituximab, she rapidly achieved clinical remission and, unexpectedly, steadily recovered glomerular filtration rate, plateauing at 25 ml/min/1.73 m(2). Peritoneal dialysis could be discontinued for 16 months. This case documents a potent beneficial effect of rituximab on renal manifestation of GPA even in long-

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FG - Pediatrie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pediatric Nephrology

ISSN

0931-041X

e-ISSN

—

Svazek periodika

28

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

511-514

Kód UT WoS článku

000314038000020

EID výsledku v databázi Scopus

—